Suppressed Programmed Death 1 Expression on CD4+ and CD8+ T Cells in Psoriatic Patients
Table 2
The distribution of PBMCs and PD-1 expression in the psoriatic patients compared to the control group.
PBMC and PD-1 expression
IU
Psoriasis
Control
Logistic regression analysis (psoriasis versus control)
M ± SD
M ± SD
OR (95% CI)
OR-1 (%)
p
CD3+
Cells/μL
1146.4 ± 408.5
964.1 ± 339.9
1.001 (1.000, 1.002)
0.1
0.041
%
59.2 ± 13.0
48.2 ± 17.0
1.051 (1.024, 1.080)
5.1
<0.001
CD4+
Cells/μL
687.2 ± 351.4
525.3 ± 253.2
1.001 (1.000, 1.002)
0.1
0.092
%
59.4 ± 18.2
54.0 ± 17.5
1.017 (0.997, 1.037)
1.7
0.103
CD8+
Cells/μL
349.2 ± 215.5
235.6 ± 144.7
1.004 (1.002, 1.006)
0.4
0.001
%
31.0 ± 16.8
23.3 ± 10.1
1.039 (1.012, 1.068)
3.9
0.005
CD4+PD-1+
Cells/μL
14.1 ± 11.3
14.7 ± 9.8
0.972 (0.940, 1.004)
−2.8
0.089
%
2.0 ± 1.2
2.9 ± 1.7
0.631 (0.475, 0.837)
−36.9
0.001
CD8+PD-1+
Cells/μL
10.2 ± 8.3
17.8 ± 19.7
0.967 (0.939, 0.996)
−3.3
0.024
%
3.3 ± 2.1
6.6 ± 4.4
0.705, (0.602, 0.824)
−29.5
<0.001
PBMCs: peripheral blood mononuclear cells; PD-1: programmed death 1; M: mean value; SD: standard deviation; OR: odds ratio; cells/μL: number of lymphocytes/μL.
